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Retinitis pigmentosa (RP) is a group of genetically and clinically heterogeneous inherited 
retinal degenerative diseases with no known cure to date. The recent gene therapy treatment 
for Leber’s congenital amaurosis and RP caused by mutations in RPE65 have resulted in 
dramatic improvements in vision, leading to excitement for other potential gene therapies on 
the horizon. Upcoming clinical trials will be targeting patients with specific mutations, and 
measurements of disease progression will be needed for each genetic subtype of RP in 
order to determine whether treatments are successful. In this retrospective cohort study, we 
examined 27 RP patients with confirmed autosomal dominant mutations in the rhodopsin 
gene by monitoring rates of progression as measured structurally with ellipsoid zone (EZ) 
line width on spectral domain optical coherence tomography (SD-OCT), horizontal and 
vertical hyperautofluorescent ring diameters on short wavelength fundus autofluorescence 
(SW-FAF), and as measured functionally with 30 Hz flicker amplitudes on 
electroretinography (ERG). Each structural parameter was measured twice by the author 
four weeks apart. The mean rates of progression were -158.5 μm per year (-8.4%) for EZ 
line widths, -122.7 μm per year (-3.5%) for horizontal diameters, and -108.3 μm per year 
(-3.9%) for vertical diameters. High test-retest reliability was observed for the parameters (EZ 
line intraclass coefficient [ICC] = 0.9989, horizontal diameter ICC = 0.9889, vertical diameter 
ICC = 0.9771). The three parameters were also correlated with each other (r = 0.9325 for EZ 
line and horizontal diameter; r = 0.9081 for EZ line and vertical diameter; r = 0.9630 for 
horizontal and vertical diameters). No significant changes in ERG amplitude were seen.  The 
subjects were classified by rhodopsin mutation class (I, IIa, IIb, III) and morphology of the 
hyperautofluorescent ring (typical vs. atypical). No significant differences in rates of structural 
progression were observed by rhodopsin mutation class or by ring morphology. Finally, 
higher rates of asymmetry of progression between the left and right eyes were detected for 
EZ line width (23% of subjects), horizontal diameter (17%), and vertical diameter (25%), as 
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Retinitis pigmentosa (RP), a group of inherited retinal diseases with an incidence 
of approximately one in 4000 people, is characterized by progressive 
photoreceptor death and irreversible vision loss (1). Typically, the initial loss of 
photoreceptors primarily involves the rods, thereby diminishing peripheral and 
night vision, followed by worsening tunnel vision and eventual loss of central 
vision mediated by cone photoreceptor death (1). Ophthalmoscopic hallmarks of 
the disease include retinal arteriolar attenuation, bone-spicule peripheral pigment 
deposits, and waxy pallor of the optic disc (2). The clinical presentation of retinitis 
pigmentosa is highly variable. The severity and pattern of vision loss may be mild 
or severe. The rate of disease progression can be slow or rapid, and the age of 
onset can be as early as childhood while some individuals remain asymptomatic 
until mid-adulthood. Allelic heterogeneity, in which each gene locus may have 
different mutations that cause the same disease entity, contributes to the diverse 
genetic etiology of RP; for example, over 300 different RPGR mutations have 
been identified in families with X-linked RP (3). Even among members of the 
same family, the same mutation may result in different phenotypic 
manifestations. RP is also a genetically heterogeneous disease, with over 50 
genes that have been found to be associated with non-syndromic RP. Further 
complicating the heterogeneity of the disease is that different mutations in the 
same gene may result in different modes of inheritance. The pattern of 
inheritance can be autosomal recessive (15-20%), autosomal dominant (20-
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25%), X-linked recessive (10-15%), or sporadic (30%) (2, 4). RP may also be 
syndromic, as seen in Bardet-Biedl syndrome, Usher syndrome, 
abetalipoproteinemia (Bassen-Kornzweig syndrome), and phytanic acid oxidase 
deficiency (Refsum disease) (2).  
 
Despite the genetic complexity of RP, improvements in the cost and efficiency of 
molecular techniques that allow for the high-throughput DNA sequencing of 
patients have resulted in clinicians being able to append a molecular diagnosis to 
their clinical diagnosis. Specifically, the advent of next-generation sequencing 
(NGS), which is able to perform massively parallel sequencing runs on the order 
of millions of DNA fragments using micron-sized beads, has dramatically 
increased the speed of sequencing many-fold and enabled the capture of a 
broader spectrum of mutations compared to conventional Sanger sequencing (5).  
 
Molecular basis of the visual cycle 
 
To understand how mutations in certain genes may cause RP, an outline of the 
visual cycle will need to be described. The first step in vision occurs when light 
enters the eye and is focused by the cornea and lens onto the retina 
(photosensitive tissue located posteriorly within the eye). In the retina, the light-
sensitive photoreceptor cells called rods and cones convert the external light 
stimuli into electrical impulses that the brain processes to form an image. Rod 
photoreceptors contain the visual pigment rhodopsin, which is a light-sensitive G-
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protein coupled receptor that consists of the apoprotein opsin and 11-cis-retinal, 
a chromophore. When light is absorbed by rhodopsin, the 11-cis-retinal is 
converted to all-trans-retinal and leads to a series of conformational changes of 
the opsin that activates the GTP-binding protein transducin, triggering a 
canonical cyclic guanosine monophosphate (cGMP) second-messenger cascade 
through the activation of cGMP phosphodiesterase (PDE) (2). PDE hydrolyzes 
cGMP, leading to closure of the cGMP-dependent cation channels normally 
responsible for influx of Na+, Ca2+, and Mg2+. The resulting hyperpolarization of 
the photoreceptor cell decreases the rate of transmitter release and elicits 
responses in second-order (bipolar) cells for further neural transmission (6). The 
all-trans-retinal is converted to all-trans-retinol and is transported to the retinal 
pigment epithelium (RPE) to be recycled into 11-cis-retinal for transport back into 
the rods (2).  
 
Rods are sensitive to low levels of light, and psychophysical experiments have 
shown that they can register single photon absorptions (6). Since rods play a 
crucial role in enabling vision in low-light scenarios and are anatomically located 
in the periphery of the retina, RP patients usually experience night blindness 
(nyctalopia) and loss of peripheral vision as their initial symptoms.  
 
The organization of the rod photoreceptor consists of a synaptic body that 
interfaces with the bipolar/horizontal cells, a cell body, an inner segment (IS) 
which contains the endoplasmic reticulum, mitochondria, and Golgi apparatus, 
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and an outer segment (OS) which houses membranous discs containing mostly 
opsin within a plasma membrane. The IS and OS are connected by the 
connecting cilium, and the OS interfaces with and is phagocytosed by the RPE.  
 
Figure 1. a) Illustration showing cell organization within the retina. b) Cross-
sectional H&E stain of retina. Image from Wikimedia Commons. 
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Structure of rhodopsin 
 
As previously mentioned, rhodopsin (RHO) is the G-protein coupled receptor 
(GPCR) that is responsible for the first step in allowing rod photoreceptors to 
detect light. It is synthesized in the rough endoplasmic reticulum and then 
transported through the Golgi apparatus where it ultimately functions within the 
discs of the OS (7). 30% to 40% of all autosomal dominant RP (adRP) is caused 
by mutations in the RHO gene, and over 120 different mutations in RHO have 
been identified (2, 8). One study of 200 families with clinical evidence of adRP 
found that rhodopsin mutations were the most common cause of disease, 
representing 26.5% of the total cases of adRP (9). In addition to its role in adRP, 
rhodopsin was the first GPCR whose crystal structure was elucidated, and it 
served as a prototype template for understanding the rest of the GPCR 
superfamily (8). Rhodopsin is a highly conserved protein among vertebrate 
species, and similar proteins have even been found in the visual systems of 
invertebrates such as Drosophila melanogaster (10). The structure of rhodopsin 
consists of four specialized domains that assist in the maintenance of protein 
structure, trafficking, and phototransduction: 1) cytoplasmic, 2) intradiscal, 3) 
transmembrane, and 4) ligand-binding domains (11). The cytoplasmic C-terminal 
domain of rhodopsin regulates its trafficking and interactions with other proteins 
in the phototransduction cascade such as transducin (11). The intradiscal domain 
contains the extracellular loops between transmembrane domains and the N-
terminus. Research suggests that mutations in the intradiscal domain result in 
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misfolding of the protein and accumulation of the protein within the secretory 
system, leading to disease (12). The transmembrane domains have been shown 
to have several residues that are important for rhodopsin protein stability and 
function (13). The ligand-binding domain is where the 11-cis-retinal chromophore 
binds with the opsin apoprotein (14).  
 
Biochemical classification of rhodopsin mutations 
 
Mutations in rhodopsin causing adRP have been grouped into three classes 
(Table 1) based on the phenotypes of the proteins from in vitro studies that 
transfected human tissue culture cells with wild-type and mutant rhodopsin cDNA 
clones (8, 11, 12). Class I mutations are located near the C-terminus of the 
protein or within the first transmembrane segment. The protein resembles wild-
type rhodopsin in terms of protein levels, ability to associate with the 11-cis-
retinal chromophore, and subcellular localization (15, 16). However, these 
mutations cause rhodopsin to activate transducin inefficiently in the presence of 
light (17). Class II mutations cause decreased binding to 11-cis-retinal and result 
in accumulation within the endoplasmic reticulum, possibly due to issues with 
protein folding and stability (15, 17). Within class II, further subclassification can 
be made for those mutants that predominantly localize intracellularly (class IIa) 
and those that preferentially localize to the cell surface (class IIb) (16). Finally, 
class III mutants form rhodopsin poorly and at low levels, are retained in the 
endoplasmic reticulum, and may form aggresomes, causing targeted degradation 
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by the ubiquitin proteasome system (18). Studies have suggested that impaired 
endocytic activity is the primary mechanism by which class III mutations cause 
RP (19). One common finding among all three classes of mutations is the 
decreased sensitivity to light and less efficient activation of transducin (17).  
 
Table 1. Classification and description of rhodopsin mutants  
Class Biochemical phenotype 
I 
Mutations occur near C-terminus 
Similar to wild-type rhodopsin 
Inefficient activation of transducin 
II 
Misfolding/instability 
Accumulation within endoplasmic reticulum 
Class IIa: localize intracellularly 
Class IIb: localize to cell surface 
III 
Impaired endocytosis from membrane 
Form rhodopsin chromophore poorly 
Accumulation within endoplasmic reticulum 
 
Clinical classification of rhodopsin patients 
 
Aside from the preceding classification of rhodopsin mutations based on 
biochemical characteristics, research on adRP caused by rhodopsin mutations 
has produced evidence of two different subtypes predicated on the clinical 
pattern of disease. The class A phenotype, sometimes referred to as “type 1” or 
“diffuse” subtypes, is characterized by a severe, early-onset diffuse loss of rod 
sensitivity with a later prolonged degeneration of cones (20, 21). The class B 
phenotype, also known as “type 2” or “regional”, exhibits a combined loss of rod 
and cone sensitivity in a superior hemifield (altitudinal) pattern with relatively 
preserved function in the inferior hemifield, as well as a slower progression of 
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disease with night blindness manifesting during adulthood (21). Because of the 
regionalized retinal degeneration in the altitudinal pattern, these phenotypic 
variants of RP are also known as sector RP (22). It has been postulated that the 
more severe class A phenotype may be caused by a gain-of-function mutation 
that is cytotoxic, while the milder class B phenotype is a result of a loss-of-
function mutation inherited on a single allele (23).   
 
Potential for therapeutic intervention 
 
Gene therapy is an experimental technique that seeks to treat genetic disorders 
by replacing or supplementing the mutated gene with a healthy copy of the gene, 
or inactivating a mutated gene, in contrast to traditional therapies such as 
surgery and medications. In late 2017, Spark Therapeutics’ LUXTURNA™ 
(voretigene neparvovec), a treatment for LCA and RP caused by mutations in the 
RPE65 gene, became the first gene therapy for any disease to gain regulatory 
approval in the United States by the Food and Drug Administration. This gene 
therapy involves the subretinal injection of wild-type copies of RPE65 packaged 
in an adeno-associated virus (AAV).  
 
RPE65 (retinal pigment epithelium-specific protein, 65 kDa) is responsible for 
producing the isomerase enzyme that catalyzes the isomerization of all-trans-
retinal back to 11-cis-retinal within the retinal pigment epithelium so that the 
previously mentioned visual cycle can begin again (24). In LCA and RP caused 
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by bi-allelic mutations in RPE65, the visual cycle is disrupted and photoreceptors 
undergo dysfunction and degeneration, the two pathological mechanisms that 
ultimately lead to progressive blindness (25). Early preclinical studies in mouse 
and dog models have shown that gene augmentation therapy is able to correct 
the biochemical blockade and result in significant, persistent vision improvement 
(25). These promising initial results over the past two decades led to the 
University of Pennsylvania research group to collaborate with Spark 
Therapeutics to test the efficacy and safety of AAV2-hRPE65v2 (voretigene 
neparvovec) on 31 patients across two leading US academic centers for the 
study of inherited retinal dystrophies (Children’s Hospital of Philadelphia, 
Philadelphia, PA and University of Iowa, Iowa City, IA). This randomized 
controlled study, the first phase 3 trial for any gene therapy, demonstrated 
clinically and statistically significant improvements in the subjects’ visual field 
measurements and ability to independently navigate in low-light conditions, 
persisting throughout the one-year follow-up period (26).  
 
The success of the RPE65 gene therapy trials has spawned a large number of 
clinical trials seeking to use gene therapy to cure other inherited retinal 
degenerative diseases. For example, there are several endeavors in the US and 
the UK to study gene therapy treatments for choroideremia, an X-linked 
recessive retinal disease that causes progressive loss of peripheral vision and 
night blindness (27, 28). Choroideremia is caused by mutations in the CHM 
gene, which encodes for the Rab escort protein-1 (REP1). This condition is 
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amenable to treatment with gene therapy using an adeno-associated virus 2 
(AAV2) capsid due to the relatively small size of the CHM cDNA payload that can 
be contained with the AAV2 vector (28).  
 
However, unlike the loss-of-function mutations of the recessive choroideremia 
and LCA that can be addressed with simple replacement of the wild-type gene, 
RP caused by a dominant RHO mutation acquires an abnormal gain of function 
that requires suppression of the mutant RHO gene and replacement with the 
wild-type version. Strategies for suppressing the toxic gene include 
transcriptional silencing, RNA interference, and ablation or correction of the 
mutation at the DNA level using gene editing techniques such as zinc finger 
nucleases (ZFNs), transcription activator-like effector-based nucleases 
(TALENs), and the recently discovered clustered regularly interspaced 
palindromic repeats (CRISPR)/Cas9 system. For RHO-adRP specifically, efforts 
over the past few decades have focused on either targeting specific mutant 
alleles for reduction in expression levels or by implementing a mutation-
independent knockdown strategy (29-31). The mutation-independent strategy is 
particularly useful given the heterogeneity of the disease due to the large number 
of disease-causing RHO mutations. This generally involves silencing the 
expression of both the mutant and wild-type RHO alleles, while supplementing 
wild-type protein-encoding RHO cDNA that is modified to be resistant to the 
suppressor. Various methods exist to silence gene expression, including RNA 
interference (RNAi) via short hairpin RNA (shRNA) or small interfering RNA 
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(siRNA), CRISPR/Cas9, and TALENs (32). One way of conferring resistance to 
the replacement RHO cDNA is to modify codons to contain wobble nucleotides at 
the target site, thereby decreasing hybridization with the suppressor reagent (33).  
 
The goal of finding treatments that are targeted to each specific genetic disorder 
is timely given the launch of the United States Precision Medicine Initiative during 
President Barack Obama’s tenure. There has been an increased interest among 
the scientific and medical communities to discover “precision medicine” 
treatments tailored to each individual’s variability in genes, environment, and 
lifestyle (34). Given the inevitable progress within the next decade in the field of 
gene therapy in the wake of LUXTURNA, there is a crucial obligation to 
characterize the natural history progression of each disease on a gene-by-gene 
basis. Without baseline measurements of disease progression rates and 
asymmetry between eyes, it will be difficult to determine the efficacy of retinal 
gene therapy even with an untreated control eye.  
 
Structural and functional assessments 
 
Various structural and functional measures of disease severity exist within the 
field of ophthalmology. Visual acuity and visual field testing are able to capture 
the patient’s perception of visual impairment, but they are subjective tests that 
have low test-retest reliability (35, 36). An objective method of assessing visual 
function is electroretinography (ERG). This noninvasive electrophysiologic test of 
12 
 
retinal function uses recording electrodes placed on the corneal surface and 
measures the changes in electric potential (against a reference electrode placed 
on the skin) in response to light stimuli of varying intensities under dark- and 
light-adapted conditions. The stimulation of the retina produces characteristic 
waveforms that provide information about the function of different cells within the 
retina, such as rods, cones, bipolar cells, retinal ganglion cells, and amacrine 
cells. Important parameters of the waveform include the a- and b-wave 
amplitudes (distance from baseline to a-wave trough, and from a-wave trough to 
b-wave peak, respectively) and implicit time (time between stimulus onset and 
maximum amplitude). The ERG is a useful tool in diagnosing many retinal 
conditions, including retinitis pigmentosa, congenital stationary night blindness, 
achromatopsia, toxic retinopathies, and cancer-associated retinopathy (37). It 
also has utility in objectively assessing the retinal function in animal research 
models. There are different forms of ERG, such as the standardized full-field 
ERG (ffERG) which measures the total retinal response, pattern ERG (PERG) 
which assesses central retinal function, and the multifocal ERG (mfERG) which 
can detect localized responses in precise regions of the retina within the central 
30 degrees (38). ERGs have shown increased reproducibility of measurements 
compared to visual field testing, but are limited in their ability to reliably detect 
small variations such as in end-stage retinal disease (35).  
 
Imaging modalities such as spectral-domain optical coherence tomography (SD-
OCT) and fundus autofluorescence (FAF) have also been shown to be practical 
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tools in providing data about retinal and RPE structures that correlate well with 
disease progression and functional measures (39). With the loss of 
photoreceptors in the periphery that gradually progresses towards the fovea seen 
in RP, it is important to be able to visualize and differentiate between the 
dysfunctional, diseased portions and the healthy viable regions of the retina. One 
visual marker of this border is the parafoveal ring of increased autofluorescence 
first shown to be correlated with PERG by Robson et al. in 2003 (40). The short-
wavelength autofluorescence (SW-AF) imaging technique uses blue light 
excitation at 488 nm and detects signals originating from lipofuscin granules and 
other fluorophores within the RPE/photoreceptor complex (41). In RP patients, 
these signals may manifest as rings and are thought to be the transition between 
healthy and diseased retinal areas, with normal function within the ring and 
dysfunction outside the ring (42). Some researchers have theorized that the 
increased intensity of the autofluorescence signal is due to atrophy or stress-
induced accumulation of lipofuscin – the oxidative byproduct of phagocytosed 
photoreceptor outer segments – within the RPE (43). The maximum intensity of 
the signal captured by FAF may therefore represent the distribution of active 
degeneration of photoreceptors where there is a high rate of phagocytosis by the 
RPE; dark areas seen on fundus autofluorescence are indicative of atrophy of 
the RPE and corresponding loss of lipofuscin granules (44). Studies have 
demonstrated that the rate of hyperautofluorescent ring constriction is correlated 
with visual field loss progression and has prognostic value in predicting visual 




In addition to FAF, SD-OCT is another noninvasive imaging modality that can 
allow for in vivo visualization of the retinal layers. One hyperreflective band layer 
that can provide information about photoreceptor health and function is the 
ellipsoid zone (EZ), previously known as the inner segment/outer segment 
(IS/OS) line (though the precise anatomic origins continue to be a topic of 
debate). The hyperreflectivity of the EZ likely corresponds with the light scattering 
by the mitochondria within the distal portion of the inner segment (46). Disruption 
and/or shortening of the EZ line width corresponds with loss of visual field 
sensitivity and thus provides a structural marker for the visual field edge (47, 48). 
Some studies have shown that measurement of the EZ line width may be more 
sensitive than full-field ERG and standard visual field testing in detecting 
progression of visual field changes in RP. Birch et al. found that the rate of 
change in EZ line width is consistent with those reported for ERGs and visual 
fields, yet the test-retest variability of the EZ line width was considerably lower 
(39). Furthermore, Birch et al. showed that the edge of the EZ line is where the 
visual field sensitivity changes most accurately, and that observing this region is 
more sensitive in detecting disease progression than global measurements that 
average across the entire field (i.e., monitoring the healthy macula and the 





Figure 2. SD-OCT image showing retinal layers. Red arrow heads pointing to ellipsoid zone line 















Statement of Purpose 
 
Retinitis pigmentosa (RP) is a group of inherited retinal degenerative diseases affecting 
roughly one in 4000 people worldwide and manifests as a progressive loss of vision. The 
pattern of visual loss generally involves the initial degeneration of the rod 
photoreceptors, followed by loss of the cones. It is marked by clinical and genetic 
heterogeneity, with varying rates of vision loss and levels of disease severity, different 
modes of inheritance, and more than 100 genes whose mutations have been found to 
cause RP. There is currently no known cure for RP, but the recent groundbreaking FDA-
approved gene therapy treatment (LUXTURNA™) for Leber’s congenital amaurosis and 
RP caused by mutations in RPE65 has shown dramatic improvements in vision and 
given promise that gene therapy is a viable strategy for treating inherited retinal 
diseases.  
 
For future gene therapy clinical trials, it will be crucial to have data regarding RP natural 
disease history and appropriate outcome measurements on a gene-by-gene basis given 
the heterogeneity of the disease. Furthermore, precise details about disease severity 
based on the various types of mutations within a single gene would inform researchers 
about their decisions to enroll patients with certain mutations. In this study, we seek to 
examine a subset of autosomal dominant RP patients with known mutations in the 
rhodopsin gene (RHO) using structural (ellipsoid zone line width, hyperautofluorescent 
ring diameters) and functional (electroretinography) assessments to monitor disease 
progression. We will also look for asymmetry of rates between eyes and any correlations 







This study was conducted in adherence to the tenets of the Declaration of 
Helsinki. All study procedures were defined and approved by the Institutional 
Review Board at the Edward Harkness Eye Institute and Columbia University 
Medical Center (Protocol #AAAR0284). Patient consent was obtained from all 
subjects. The patient data presented here, including images and genetic testing 
results, are not identifiable to individual patients. Diagnoses of RP were made by 
an inherited retinal disease specialist (S.H.T.) based on clinical history, fundus 
examinations, and full-field electroretinography (ffERG) results. This is a 
retrospective cohort study with the following inclusion criteria: 1) patients must 
have genetic sequencing-confirmed RHO mutations; and 2) a complete 
ophthalmic examination must have been performed by our retinal disease 
specialist on at least one visit. Since our clinic is an international referral center 
for patients with RP, a significant portion of the subjects had their care 
transferred back to their primary provider after the initial diagnosis was made in 
our clinic using imaging, electroretinography, and genetic testing and thus did not 
return for a follow-up visit. Patients were excluded if they: 1) presented with 
advanced stage RP with no visible ellipsoid zone line in any eye at all time 
points; 2) had unilateral RP; 3) did not have any visible hyperautofluorescent ring 
in any eye at all time points; and 4) had poor image quality. A total of 38 patients 
fit our inclusion criteria; 11 patients were excluded based on the exclusion 
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criteria, leaving a total of 27 patients on whom to base our analysis. The 38 
patients belonged to 21 different families; the final 27 subjects belonged to 18 
different families. For the 27 patients who were studied, eyes were analyzed only 
if there were visible EZ lines/hyperautofluorescent rings; if there were no EZ 




DNA was extracted from the blood obtained from patients and was tested for 
previously published RP genes of the Chiang panel at Columbia University 
Medical Center Department of Pathology and Oregon Health Sciences 
University. Parallel sequencing was performed using the Illumina HiSeq platform 
with 100 bp paired-end reads, and mutations were confirmed by dideoxy chain-
terminating sequencing. 
 
Mutation classification  
 
Each patient was assigned a biochemical rhodopsin mutation classification 
based on PubMed literature searches for each specific mutation. Biochemical 
classifications were found for 32 out of 38 patients. Patients 3 and 4 had 
mutations that have not been studied and classified. For patients 6-9, the 
mutations were studied in bovine rhodopsin and were not characterized using the 
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classification system proposed by Sung et al. (16, 50, 51). Table 2 lists the 
mutation classifications as well as their corresponding literature references.  
Table 2: Rhodopsin biochemical mutation classification, including excluded patients 
 Genotype Mutation class Reference 
1 RHO (c.556T>C:p.Ser186Pro) IIa PMID8253795 
2 RHO (c.937-27_-19delCCCTGACTC) I PMC52606 
3 RHO (c.946delT:p.Cys316Alafs*44) -  
4 RHO (c.946delT:p.Cys316Alafs*44) -  
5 RHO (c.266G>A:p.Gly89Asp) IIb PMC52606 
6 RHO (c.83A>G:p.Glu28Arg) -  
7 RHO (c.328T>C:p.Cys110Arg) -  
8 RHO (c.328T>C:p.Cys110Arg) -  
9 RHO (c.328T>C:p.Cys110Arg) -  
10 RHO (c.568G>A:p.Asp190Asn) IIa PMID8253795 
11 RHO (c.568G>A:p.Asp190Asn) IIa PMID8253795 
12 RHO (c.266G>Ap.Gly89Asp) IIb PMC52606 
13 RHO (c.1025G>A:p.Thr342Met) I PMC52606 
14 RHO (c.541G>A:p.Glu181Lys) IIa PMID8253795 
15 RHO (c.800C>T:p.267Leu) IIa PMID8253795 
16 RHO (c.316G>A:p.Gly106Arg) IIb PMID8253795 
17 RHO (c.404G>T:p.Arg135Leu) III PMC437971 
18 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
19 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
20 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
21 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
22 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
23 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
24 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
25 RHO (c.800C>T:p.267Leu) IIa PMID8253795 
26 RHO (c.632A>C:p.His211Pro) IIa PMID8253795 
27 RHO (c.50C>T:p.Thr17Met) IIa PMC52606 





30 RHO (c.68C>A:p.Pro23His) IIa PMC52606 
31 RHO (c.68C>A:p.Pro23His) IIa PMC52606 
32 RHO (c.68C>A:p.Pro23His) IIa PMC52606 
33 RHO (c.68C>A:p.Pro23His) IIa PMC52606 
34 RHO (c.68C>A:p.Pro23His) IIa PMC52606 
35 RHO (c.68C>A:p.Pro23His) IIa PMC52606 
36 RHO (c.403C>T:p.Arg135Trp) III PMC437971 
37 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 
38 RHO (c.1040C>T:p.Pro347Leu) I PMC52606 




Image acquisition and measurements 
 
Imaging was conducted after adequate pupil dilation (>7 mm) using 
phenylephrine hydrochloride (2.5%) and tropicamide (1%). Fundus 
autofluorescence (FAF, 488 nm excitation) and horizontal 9 mm SD-OCT images 
at the fovea were acquired using the Spectralis HRA+OCT (Heidelberg 
Engineering, Heidelberg, Germany) at each visit. OCT imaging was assisted by 
eye-tracking technology that enables accurate and reproducible scans at the 
same location on the fovea across multiple visits. The images were recorded with 
a 30-degree field of view; in cases where the rings were too large to be 
visualized with the 30-degree field of view, scans with a 55-degree field of view 
were also captured.  
 
The ellipsoid zone line widths, and horizontal and vertical diameters of the 
hyperautofluorescent ring were manually measured using the built-in measuring 
tool provided by the Spectralis software. The ellipsoid zone line width was 
measured between the nasal and temporal limits of the ellipsoid zone layer using 
the horizontal foveal scan on SD-OCT. The external border of the 
hyperautofluorescent ring was used to determine diameter length, as it is more 
clearly defined and easily visualized compared to the internal border. The 
horizontal diameter is oriented along the axis formed by the center of the fovea 
and the center of the optic disc. The vertical diameter is defined as the length of 
the line between the external ring border, perpendicular to the horizontal 
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diameter and passing the center of the fovea (Figure 3). For each parameter 
(ellipsoid zone line width, horizontal and vertical diameters of the autofluorescent 
ring), two measurements were taken by the author (L.C.) four weeks apart for 
each studied image in order to assess for test-retest reliability. Cystoid macular 
edema (CME) was also noted if it significantly present in the OCT images. The 
hyperautofluorescent rings seen on FAF were qualitatively categorized as either 
typical (uniformly round, ellipsoidal rings) or atypical (any ring that deviates from 
the typical morphology). Figure 4 shows an example of typical vs. atypical ring 
morphology. 
 
Figure 3. Short wavelength fundus autofluorescence (SW-FAF) image of left eye. Red: horizontal 




Figure 4. Examples of various forms of hyperautofluorescent ring morphology on fundus 
autofluorescence (FAF) imaging. Left: typical, uniformly round, ellipsoidal ring. Middle: atypical, 
irregularly shaped autofluorescence surrounded by regions of atrophy. Right: atypical, arcuate 




Full-field electroretinography (ffERG) was performed using disposable corneal 
low-impedance corneal DTL electrodes and the Diagnosys Espion 
Electrophysiology System (Diagnosys LLC, Lowell, MA, USA) on both eyes in 
accordance to the International Society for Clinical Electrophysiology of Vision 
(ISCEV) standards. Dark-adapted 0.01 cd·s·m^-2 stimulus strength (rod 
response), dark-adapted 3.0 cd·s·m^-2 (combined rod-cone response), light-
adapted 3.0 cd·s·m^-2 (single-flash cone response), and light-adapted 3.0 
cd·s·m^-2 flicker (30 Hz flicker) ERG recordings were obtained. The patients 
were dark-adapted for a minimum of 20 minutes before the scotopic ERG 
measurements and were light-adapted for a minimum of 10 minutes prior to the 
photopic ERG tests. For patients with 30 Hz flicker amplitudes less than 5 uV or 
who were predicted to have less than 5 uV based on clinical examination, bipolar 
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Burian-Allen contact lens electrodes were used with narrow bandpassed filtering 
and computed averaging in order to minimize electrical artifacts and noise when 
measuring small amplitude cone responses (52). The 30 Hz flicker data were 
used for analysis as it is a commonly used outcome measure of visual function in 
RP patients (52). Because rod function is usually the first to be affected in RP, 
the scotopic ERG responses are typically markedly diminished at presentation, 
making the 30 Hz flicker cone ERG response (Figure 5) a useful prognostic 

















Figure 5. 30 Hz flicker waveform with peak, trough, and amplitude marked (green). 
 
 






For each patient in the cohort, measurements of EZ line width and horizontal and 
vertical hyperautofluorescent ring diameters were obtained from SD-OCT and 
FAF images, respectively, from the most recent visit and the first visit if the 
patient was seen more than once in our clinic. The widths and diameters were 
measured by the author (L.C.) four weeks apart to determine test-retest 
reliability. The intraclass correlation coefficient (ICC) was calculated for each 
structural parameter to determine the reliability of the test-retest measurements. 
To calculate the correlation between each pair of parameters, the Pearson 
correlation coefficient was used based on the average of the two test-retest 
measurements. The rate of progression was calculated for each parameter by 
taking the difference between the value from the most recent visit and the value 
from the first visit, divided by the length of follow-up. In order to test for symmetry 
of the right and left eyes (i.e., whether the progression rates of the right and left 
eyes were similar), the difference in progression rates between the eyes was 
compared to the variability of test-retest measurements of the right eye. All 
statistical analyses were performed using Stata 12.1 (StataCorp LP, College 











A total of 38 patients were identified as having adRP caused by mutations in the 
RHO gene. 11 patients were excluded from the study as a result of having 
advanced-stage disease with no visible EZ line at any time point, leaving 27 
patients in our analysis. Sixteen (59.3%) patients were female and eleven 
(40.7%) were male. The average age of patients at the initial visit was 44.0 years 
(standard deviation 17.7 years, range 15-78 years). Sixteen patients had 
measurements from more than one clinic visit, while eleven patients were 
examined at only one clinic visit and thus did not receive any analysis for disease 
progression. The age distribution of patients with data from multiple clinical visits 
is shown in Table 3. The average length of follow-up for patients with more than 
one visit was 4.3 years (standard deviation 2.8 years). A total of 20 patients had 
typical symmetric ellipsoid-shaped hyperautofluorescent rings, and 7 had atypical 
rings that deviated from the typical morphology. Six patients were observed to 
have cystoid macular edema (CME) in either eye. The results are summarized in 
Table 4. 
 
Table 3: Age distribution of subjects with multiple clinical visits 
n Mean age (years) Standard deviation 
Quantiles 
Minimum 25th Median 75th Maximum 




Table 4. Genotype, demographic, and clinical characteristics of study subjects  












1 23 F RHO (c.937-27_-19delCCCTGACTC) 6.8 + I  
2 71 M RHO (c.946delT:p.Cys316Alafs*44)   N/A + 
3 44 F RHO (c.266G>A:p.Gly89Asp) 0.5 + IIb + 
4 46 F RHO (c.328T>C:p.Cys110Arg) 2.8 + N/A  
5 16 F RHO (c.328T>C:p.Cys110Arg) 2.8 + N/A  
6 69 F RHO (c.328T>C:p.Cys110Arg) 6.4  N/A  
7 15 M RHO (c.568G>A:p.Asp190Asn) 3 + IIa  
8 59 M RHO (c.568G>A:p.Asp190Asn) 7 + IIa  
9 43 M RHO (c.266G>Ap.Gly89Asp) 7  IIb + 
10 56 F RHO (c.1025G>A:p.Thr342Met) 8.3 + I  
11 39 F RHO (c.541G>A:p.Glu181Lys) 0.1  IIa  
12 66 M RHO (c.800C>T:p.267Leu) 8 + IIa  
13 78 M RHO (c.316G>A:p.Gly106Arg) 5.7 + IIb + 
14 37 F RHO (c.404G>T:p.Arg135Leu) 3.7 + III  
15 34 F RHO (c.1040C>T:p.Pro347Leu)  + I  
16 28 M RHO (c.1040C>T:p.Pro347Leu)  + I  
17 46 M RHO (c.1040C>T:p.Pro347Leu)  + I  
18 49 M RHO (c.632A>C:p.His211Pro)  + IIa  
19 19 M RHO (c.50C>T:p.Thr17Met)  + IIa  
20 28 F RHO (c.50C>T:p.Thr17Met) 4.2 + IIa  
21 56 F RHO 
(c.404_405delinsGG>TT:p.Arg135Leu) 
1.7  III  
22 37 F RHO (c.68C>A:p.Pro23His)  + IIa  
23 56 F RHO (c.68C>A:p.Pro23His)  + IIa  
24 32 F RHO (c.68C>A:p.Pro23His)  + IIa  
25 56 M RHO (c.68C>A:p.Pro23His)   IIa + 
26 61 F RHO (c.68C>A:p.Pro23His)   IIa  
27 23 F RHO (c.1040C>T:p.Pro347Leu) 0.2 + I  
RHO = rhodopsin; CME = cystoid macular edema; N/A = mutation class unknown; + = finding is 
present 
 
Reliability of measurements 
 
The test-retest reliability was assessed using the intraclass correlation coefficient 
(ICC) for each of the three measurement parameters. Within each measurement 
parameter, the data for both eyes at all time points were pooled. The ICC for the 
ellipsoid zone line width was 0.9989, ICC for the horizontal diameter was 0.9889, 
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and the ICC for the vertical diameter was 0.9771. Graphs showing the 
intraobserver reliability of the three parameters for each eye are shown in Figure 
6.  
 
To determine the strength of linear association between each of the three 
imaging parameters, the Pearson correlation coefficient (two-tailed, α = 0.05) 
was calculated. The analysis revealed a high degree of correlation between each 
pair of parameters (scatterplots shown in Figure 7): r = 0.9325 (p < 0.0001) for 
the ellipsoid zone line and horizontal diameter measurements, r = 0.9081 (p < 
0.0001) for the ellipsoid zone line and vertical diameter measurements, and r = 
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Figure 6. Intraobserver reliability of ellipsoid zone line widths, hyperautofluorescent horizontal 
ring diameters, and vertical ring diameters of right (OD) and left (OS) eyes in a cohort of 27 
patients with autosomal dominant retinitis pigmentosa. Measurements for each parameter 
were taken four weeks apart. Line of equality shown.  
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Figure 7. Correlation of ellipsoid zone 
line widths, hyperautofluorescent 
horizontal ring diameters, and vertical 
ring diameters. Scatterplots show EZ 
line widths compared to horizontal 
width diameters (top), EZ line widths 
compared to vertical diameters 
(middle), and horizontal diameters 













































































Structural progression rate 
 
Using the structural measurements for patients with multiple time points, the 
progression rate for each parameter was calculated separately for each eye 
(Table 5). The progression rates were calculated with p-values using the null 
hypothesis μ = 0. All progression rates were found to be negative, indicating a 
decline in length over time. The mean rates of decline for the EZ line in the right 
eye was 208.7 μm/year (standard error = 49.8, p = 0.0008), EZ line in the left eye 
was 96.6 μm/year (standard error = 37.7, p = 0.0248), horizontal diameter in the 
right eye was 109.5 μm/year (standard error = 36.2, p = 0.0097), horizontal 
diameter in the left eye was 138.1 μm/year (standard error = 46.3, p = 0.0124), 
vertical diameter in the right eye was 114.2 μm/year (standard error = 30.5, p = 
0.0025), and vertical diameter in the left eye was 101.5 μm/year (standard error = 
31.6, p = 0.0083). The Wilcoxon signed-rank test was also performed for each 
imaging parameter for each eye as an alternative to the Student’s t-test without 
assuming a normal distribution for the data (Table 6).  














EZ line width OD 16 -208.7 49.8 -742.9 -172.8 -7.9 0.0008 
EZ line width OS 13 -96.6 37.7 -365 -86.9 173.9 0.0248 
Horizontal diameter 
OD 










Vertical diameter OD 14 -114.2 30.5 -411.3 -101.9 25.3 0.0025 
Vertical diameter OS 12 -101.5 31.6 -386.2 -80.3 16.2 0.0083 
EZ = ellipsoid zone; OD = right eye; OS = left eye; rates = μm per year; negative rate = 
decrease in length; positive rate = increase in length 




Table 6: p-values from Wilcoxon signed-rank test of progression rates for three imaging 
parameters 
Parameter p-value* 
EZ line width OD 0.0004 
EZ line width OS 0.0192 
Horizontal diameter OD 0.0043 
Horizontal diameter OS 0.0029 
Vertical diameter OD 0.0023 
Vertical diameter OS 0.0047 
EZ = ellipsoid zone; OD = right eye; OS = left eye 
*p-value calculated using Wilcoxon signed-rank test with null hypothesis μ = 0 
 
After the rates from both eyes were pooled to obtain an overall progression rate 
for each measurement, the mean rate of decline for the EZ line was 158.5 
μm/year (standard error = 33.4, p < 0.0001), horizontal diameter was 122.7 
μm/year (standard error = 28.5, p = 0.0002), vertical diameter was 108.3 μm/year 
(standard error = 21.6, p < 0.0001) (Table 7). Converting the progression rates in 
terms of percentages of the mean value at the initial visit yields an average 
yearly progression rate (decline) of 8.4% for the ellipsoid zone line, 3.5% for the 
horizontal diameter, and 3.9% for the vertical diameter. 
 
Table 7: Overall progression rates of the three measured imaging parameters, both eyes 
combined 
Parameter n Mean change (μm/yr) Standard error p-value* 
EZ line width 29 -158.5 33.4 <0.0001 
Horizontal diameter 26 -122.7 28.5 0.0002 
Vertical diameter 26 -108.3 21.6 <0.0001 
EZ = ellipsoid zone; rates = μm per year; negative rate = decrease in length; positive rate = 
increase in length 






Asymmetry of disease severity and progression rates between both eyes 
 
Since some of the subjects exhibited markedly different measurements between 
left and right eyes at baseline, the asymmetry of disease severity and 
progression rate between both eyes was assessed. For ellipsoid zone 
measurements, we first calculated the variability of the absolute differences 
between the right and left eyes using the average of the two intraobserver 
measurements for all time points (standard deviation = 506.8 μm). Comparison of 
this value to the variability of the absolute differences between the test and retest 
ellipsoid zone measurements of the right eye for all time points (standard 
deviation = 46.7 μm) shows that there is a greater amount of variability between 
eyes than the test-retest measurements of one eye. 
 
Next, the 95th percentile of absolute differences in EZ line progression rates 
between the test and retest measurements of the right eye was calculated (110.2 
μm/year) in order to set the threshold for quantifying the number of patients who 
had significant differences in progression rates between their left and right eyes. 
23% (3/13) of the subjects with progression data for both eyes were found to 
have absolute differences in progression rates between eyes that exceeded the 
110.2 μm/year threshold.  
 
Repeating the asymmetry analysis for the horizontal diameter measurements, we 
found that the variability between the right and left eyes (standard deviation 
33 
 
= 968.2 μm) was greater than the variability between the test and retest 
measurements of the right eye (standard deviation = 184.0 μm). The 95th 
percentile of absolute differences in horizontal diameter progression rates 
between the test and retest measurements of the right eye was 173.7 μm/year. 
17% (2/12) of the subjects with progression data for both eyes had differences in 
horizontal diameter progression rates between eyes that exceeded the 95th 
percentile threshold.  
 
For the vertical diameter, the variability between the right and left eyes (standard 
deviation = 452.0 μm) was greater than the variability between the test and retest 
measurements of the right eye (standard deviation = 214.9 μm). 25% (3/12) of 
the subjects with progression data for both eyes were found to have significantly 
different vertical diameter progression rates between eyes that exceeded the 
95th percentile of absolute differences in progression rates between the test and 
retest measurements of the right eye (117.5 μm/year).  
 
Functional progression rate 
 
ERG data was available for ten subjects, of which three patients had longitudinal 
measurements from multiple visits. The average length of ERG follow-up was 2.8 
years. Table 8 summarizes the 30 Hz flicker ERG test results. For the initial visit, 
the mean 30 Hz flicker amplitude was 22.0 μV (standard error = 7.0) in the right 
eye and 23.9 μV (standard error = 7.7) in the left eye. The mean change in 
34 
 
amplitude of the 30 Hz flicker test was an increase in 3.9 μV per year (standard 
deviation = 2.8 μV).  
 
Table 8: 30-Hz flicker amplitudes for subjects with ERG data 




























1 23 6.8 31 36 40 50 1.3 2.1 
6 69  0.7 0.2     
7 15  70 70     
11 39  3 2     
13 78 0.6 21 22 23 25 3.3 5 
14 37  4.8 2.6     
20 28 1.1 40 42 50 45 9.1 2.7 
21 56  1.5      
25 32  15 13     
29 23  33 27     
ERG = electroretinography; OD = right eye; OS = left eye; mean change was calculated only for 




Mutation class-specific measurements and progression rates 
 
Subjects were classified by rhodopsin biochemical mutation class based on a 
literature search of their genotypes, as seen in Table 2. For the 27 subjects that 
were analyzed, stratification into five groups was performed: class I, class IIa, 
class IIb, class III, and unknown class. The mean structural measurements for 
each eye and time point were calculated for each mutant group, and the results 
are summarized in Tables 9, 10, 11, 12, 13. Using these measurements, we 
calculated the rate of structural progression for each eye and each mutation 
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class (Table 14). The overall rate of structural progression after combining both 
eyes was also calculated for each mutation class (Table 15).  
 
Table 9. Class I mutation mean structural measurements, both time points  
  OD  OS 
  n Mean SD  n Mean SD 
EZ line width 
Time point 1 3 3540.3 2464.1  3 3388.8 2564.5 
Time point 2 3 2697.8 2879.9  3 3144.8 2297.0 
Horizontal 
diameter 
Time point 1 2 4396.3 2562.2  2 4317.3 2826.7 
Time point 2 2 3740.8 3101.0  2 3718.8 30147.3 
Vertical 
diameter 
Time point 1 2 4313.3 2845.0  2 3919.0 2852.5 
Time point 2 2 2916.3 2620.9  2 2870.5 2601.5 
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial 
visit; time point 2 = most recent visit. All units are in μm.   
 
Table 10. Class IIa mutation mean structural measurements, both time points  
  OD  OS 
  n Mean SD  n Mean SD 
EZ line width 
Time point 1 5 2276.6 1892.1  3 3539.5 3187.8 
Time point 2 5 1991.5 1675.6  3 3144.8 2971.3 
Horizontal 
diameter 
Time point 1 4 3348.0 2070.7  3 3799.0 2736.0 
Time point 2 4 2985.3 1694.2  3 3467.0 2836.9 
Vertical 
diameter 
Time point 1 4 2730.6 1795.1  3 3433.8 2671.9 
Time point 2 4 2305.5 1640.6  3 3129.5 2845.4 
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial 
visit; time point 2 = most recent visit. All units are in μm.   
 
Table 11. Class IIb mutation mean structural measurements, both time points  
  OD  OS 
  n Mean SD  n Mean SD 
EZ line width 
Time point 1 3 2805.7 1450.8  3 2443.2 1162.7 
Time point 2 3 2192.2 766.1  3 2034.0 802.3 
Horizontal 
diameter 
Time point 1 3 4023.5 968.6  3 3444.3 421.9 
Time point 2 3 3413.5 698.2  3 3178.8 303.8 
Vertical 
diameter 
Time point 1 3 3022.5 704.0  3 2750.7 665.5 
Time point 2 3 2774.5 639.0  3 2582.7 383.0 
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial 





Table 12. Class III mutation mean structural measurements, both time points  
  OD  OS 
  n Mean SD  n Mean SD 
EZ line 
width 
Time point 1 2 1393.3 801.5  1 1505.0 - 
Time point 2 2 899.3 1271.7  1 1569.5 - 
Horizontal 
diameter 
Time point 1 2 1920.0 856.3  1 2190.0 - 
Time point 2 2 1863.0 770.8  3 2200.5 - 
Vertical 
diameter 
Time point 1 2 1668.3 332.0  1 1805.0 - 
Time point 2 2 1687.5 437.7  1 1778.0 - 
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial 
visit; time point 2 = most recent visit; - = not available. All units are in μm.   
 
Table 13. Mean structural measurements for unknown mutation class, both time points  
  OD  OS 
  n Mean SD  n Mean SD 
EZ line 
width 
Time point 1 3 2238.5 1595.9  3 2579.5 2134.7 
Time point 2 3 1679.8 1385.9  3 1896.3 1988.4 
Horizontal 
diameter 
Time point 1 3 3409.5 1437.2  3 3682.8 1578.4 
Time point 2 3 3142.0 1525.7  3 2437.0 2404.2 
Vertical 
diameter 
Time point 1 3 2794.8 1320.8  3 3029.2 1256.6 
Time point 2 3 2409.8 1451.2  1 1998.5 2015.5 
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial 
visit; time point 2 = most recent visit; - = not available. All units are in μm.   
 
Table 14. Rate of structural progression for each mutation class, right vs. left eye 
  OD  OS 
 Mutation class n Mean SD  n Mean SD 
EZ line 
width 
Class I 3 -346.7 348.1  3 22.0 135.6 
Class IIa 5 -107.2 80.15  3 -108.4 90.8 
Class IIb 3 -237.6 203.7  3 -151.3 120.1 
Class III 2 -263.4 311.1  1 17.35 - 
Unknown 3 -174.6 115.2  3 -186.7 158.8 
Horizontal 
diameter 
Class I 2 -81.8 59.2  2 -77.2 18.1 
Class IIa 4 -103.7 132.7  3 -73.0 96.2 
Class IIb 3 -246.5 219.5  3 -178.8 229.0 
Class III 2 -14.8 23.0  1 2.8 - 
Unknown 3 -62.0 32.3  3 -250.1 195.7 
Vertical 
diameter 
Class I 2 -187.2 55.7  2 -141.3 52.8 
Class IIa 4 -102.9 90.2  3 -62.3 72.3 
Class IIb 3 -169.1 217.6  3 -48.2 60.4 
Class III 2 -3.6 40.8  1 -7.3 - 
Unknown 3 -99.6 12.1  3 -198.9 170.1 
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial 




Table 15. Rate of structural progression for each mutation class, all eyes 
 Mutation class n Mean SD p-value† 
EZ line 
width 
Class I 6 -162.3 310.8 0.2569 
Class IIa 8 -107.7** 77.6 0.0057 
Class IIb 6 -194.5* 156.9 0.0289 
Class III 3 -169.8 273.3 0.3943 
Unknown 6 -180.6* 124.2 0.0162 
Horizontal 
diameter 
Class I 4 -79.5* 35.8 0.0212 
Class IIa 7 -90.6 110.2 0.0727 
Class IIb 6 -212.7 204.0 0.0511 
Class III 3 -8.9 19.7 0.5146 
Unknown 6 -156.1 162.3 0.0651 
Vertical 
diameter 
Class I 4 -164.2** 51.6 0.0079 
Class IIa 7 -85.5* 79.3 0.0290 
Class IIb 6 -108.6 157.4 0.1519 
Class III 3 -4.8 29.0 0.8004 
Unknown 6 -149.2* 120.8 0.0292 
EZ = ellipsoid zone; SD = standard deviation. All units are in μm. †p-value calculated using one-
sample Student’s t-test with null hypothesis μ = 0. * = p-value < 0.05; ** = p-value < 0.01 
 
Ring morphology analysis 
 
The presence of a typical ellipsoidal ring or an atypical ring on fundus 
autofluorescence was noted for each patient (Table 4). The impact of the 
presence of a typical ring was examined by comparing the mean progression 
rates in the subgroup of patients with typical rings and patients with atypical 
rings. For ellipsoid zone line progression rates, patients with atypical rings (n = 6) 
had an average rate of -154.0 μm/year (standard deviation = 173.1 μm/year). 
Patients with a typical ring (n = 23) had a mean rate of -159.6 μm/year (standard 
deviation = 185.4 μm/year). A two-sample Student’s t-test (two-tailed, equal 
variance) showed a p-value of 0.947, indicating no significant difference in the 
progression rates between both groups. 
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For horizontal diameter rates, patients with atypical ring morphology (n = 5) had a 
mean change of -113.5 μm/year (standard deviation = 187.8 μm/year), and those 
with typical ring morphology (n = 21) had an average rate of -124.9 μm/year 
(standard deviation = 138.7 μm/year). No significant difference in rates was 
found on the Student’s t-test (p-value = 0.878).  
 
Examining the vertical diameters, we found that patients with atypical rings (n = 
5) had an average progression rate of -96.2 μm/year (standard deviation = 167.4 
μm/year), and patients with typical rings (n = 21) progressed by -111.2 μm/year 
(standard deviation = 97.4 μm/year). Similar to the ellipsoid zone and horizontal 
diameter analyses, no significant difference in vertical diameter progression 
















Overall, this study of progression in retinitis pigmentosa patients with autosomal 
dominant rhodopsin mutations demonstrates that ellipsoid zone line widths as 
measured by SD-OCT and hyperautofluorescent ring diameters measured by 
SW-FAF can be used to detect progression in RP, corroborating previous studies 
of disease progression in RP cohorts with varying mean lengths of follow-up (39, 
53-55). While most studies had a genetically heterogeneous group of RP patients 
with X-linked, syndromic, autosomal dominant, and autosomal recessive RP, this 
study examined only those with confirmed autosomal dominant RHO mutations. 
The mean length of follow-up for our patients was 4.3 years (SD = 2.8 years), 
while Sujirakul et al. had a 2-year mean follow-up, Takahashi et al. had an 
average follow-up of 4.5 years, and Cabral et al. had a mean length of 3.1 years 
(53-55). The mean rates of decline were 158.5 μm/year (8.4%) for EZ line widths, 
122.7 μm/year (3.5%) for horizontal diameters, and 108.3 μm/year (3.9%) for 
vertical diameters, which are comparable to rates found in previous studies (39, 
53-57).   
 
Furthermore, our results show that the three structural parameters correlate well 
with each other (r = 0.9325 for EZ line and horizontal diameter; r = 0.9081 for EZ 
line and vertical diameter; r = 0.9630 for horizontal and vertical diameters) and 
have a high degree of intraobserver reliability (ICC = 0.9989 for EZ line, ICC = 
0.9889 for horizontal diameter, ICC = 0.9771 for vertical diameter). These 
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findings confirm that structural measurements of disease progression using SW-
FAF and SD-OCT imaging modalities are reliable and objective methods of 
assessing the patient’s state of disease.  
 
Asymmetry of progression in EZ line widths, horizontal diameters, and vertical 
diameters between the left and right eyes was also observed. 23% of subjects 
had asymmetry in EZ line progression, 17% had asymmetry in horizontal 
diameter progression, and 25% had asymmetry in vertical diameter progression. 
These rates are slightly higher than rates of asymmetry found in other studies. 
One study found an overall proportion of approximately 20% of patients with 
significant asymmetry between both eyes, though the asymmetry was seen only 
in EZ line progression and not in horizontal or vertical diameter progression of 
the ring (54). Another study of patients with Usher syndrome found only a 10% 
rate of hyperautofluorescent ring asymmetry (57). A possible cause for the 
differences in observed asymmetry may be that different forms of RP, whether by 
inheritance pattern or gene mutation, are more strongly associated with 
asymmetry than others. It has been observed that some genes (RHO, PRPF8) 
implicated in autosomal dominant RP may exhibit variable expressivity (58, 59), 
and we theorize that this variability may account for the asymmetry to some 
degree. A better understanding of asymmetry in RP patients will be needed to 
properly enroll subjects and monitor disease progression in future clinical trials. 
This is also particularly important because gene therapy trials often test 
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treatment in one eye while keeping the untreated eye as an internal control, and 
asymmetry may skew results.  
 
Functional progression using the 30 Hz flicker amplitudes on electroretinography 
was also examined. The 30 Hz flicker test was chosen as a useful outcome to 
measure given that scotopic ERG responses are commonly extinguished in RP 
patients at the time of presentation. The flicker amplitudes were also used as the 
main outcome measure in the landmark trial studying the effects of vitamin A and 
E supplementation in patients with RP (60). A mean positive change (3.9 
μV/year) was observed, which is unexpected as one would expect retinal function 
to decline over time in a fashion similar to the structural measurements. This 
finding is likely due to the high test-retest variability of ERG measurements (e.g., 
recording conditions, electrodes, operator technique), relatively stable 
progression of function in slow-progressing variants of RP, and our small sample 
size (n = 3). Of the two clinical phenotypes, our few patients with longitudinal 
ERG data may likely belong to the class B phenotype, characterized by slower 
and less severe progression of disease. Studies on different types of 
retinopathies have suggested that the 30 Hz flicker amplitude may be a less 
sensitive, highly variable signal that does not correlate well with disease severity; 
instead, they propose that the 30 Hz flicker implicit time may be a more reliable 




RP is genetically heterogeneous with each gene being identified as having 
multiple possible mutations that affect gene/protein function through distinct 
mechanisms. Because of this, we sought to classify each subject by their 
rhodopsin mutation class based on their genotype and prior in vitro biochemical 
studies of rhodopsin mutants. The mean rates of structural progression were 
calculated for each mutant class. However, since the size of the cohort was small 
(n = 27), dividing the cohort further by mutation class resulted in subgroups that 
were even smaller, highly variable, and too underpowered for any statistically 
significant conclusions to be drawn from. Some of the patients (n = 3) had 
mutations that were still unclassified in the literature, suggesting further work to 
be done in studying the molecular pathogenesis of newly discovered mutations 
and their effects on protein structure. 
 
In our subjects, two patterns of hyperautofluorescent rings could be discerned: 
typical/ellipsoidal and atypical. These regions of maximal intensity on fundus 
autofluorescence with 488 nm excitation are thought to correlate to areas of the 
retina containing an abundance of lipofuscin through active degeneration of the 
photoreceptors and subsequent increased phagocytosis by the RPE. Thus, the 
ring may mark the boundary between healthy and diseased retina, as well as the 
limits of the patient’s visual field. 26% (7/27) of our cohort had atypical rings, and 
we were interested in whether the morphology of the ring was associated with 
the rate of progression. No statistically significant differences were found 
between patients with typical and atypical morphology regarding EZ line width, 
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horizontal diameter, and vertical diameter progression rates. The small size of 
the atypical ring group may have contributed to this finding; increasing the 
sample size in future studies would allow for better detection of differences if they 
do exist. 
 
The significance of determining the progression rates in this subset of adRP 
patients is three-fold: 1) this data would allow clinicians to more accurately 
counsel patients with these specific mutations regarding their prognosis, 2) future 
gene therapy trials will need to have an objective baseline of natural history 
disease progression for patients with their target genotype in order to determine 
efficacy of treatment, and 3) any results from a subset of the cohort that are 
unexpected or deviate from the rest of the subjects may provide the basis on 
which to perform further studies to elucidate mechanisms of pathogenesis and 
other factors that influence disease severity.  
 
Notwithstanding its potential significance, this study has certain limitations. The 
retrospective nature of the study may introduce selection and information biases, 
as well as result in heterogeneity of the types of data/measurements at our 
disposal. The inclusion-exclusion criteria and subsequent subgroup classification 
restricted the analysis to a small cohort of patients, which decreases the 
statistical power. Patients with severe end-stage RP were unable to be studied 
due to lack of a discernable EZ line on SD-OCT. Only three subjects had 
longitudinal ERG data, which limits any statistically significant conclusions to be 
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drawn regarding functional progression. The lengths of follow-up for patients with 
imaging data were also variable, ranging from two months to 8.3 years. Four 
patients had mutations that were unable to be classified by rhodopsin mutation 
class. Finally, the majority of subjects had typical ellipsoidal hyperautofluorescent 
rings, leaving only seven patients with atypical ring morphology,  
 
Using a combination of objective measures of visual function like the ERG and 
non-invasive imaging modalities such as OCT and FAF has good utility in 
monitoring disease progression in RP. Each modality has its own set of 
advantages and drawbacks. For example, electrophysiology can be used to 
detect early-stage disease since ERG abnormalities typically precede any 
structural changes on funduscopic and imaging exams (63). ERGs can also be 
used in determining the long-term visual prognosis of RP patients from a single 
visit based on the amplitudes of the 30 Hz flicker test (52). However, as 
previously mentioned, some of the drawbacks that make it difficult to effectively 
implement include high sensitivity to electrical noise through electronic 
interference, artifacts produced through blinking and eye movements, variability 
of waveforms produced depending on electrode positioning, relatively long 
duration of exam (~30-60 minutes), and requirement of anesthesia for use in 
pediatric populations. On the other hand, structural imaging with OCT and FAF 
can provide high-resolution images of the posterior pole of the retina with a very 
low degree of invasiveness and minimal test-retest variability. FAF imaging can 
provide data about metabolism and RPE lipofuscin accumulation that may not be 
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visible to the naked eye on fundus examination, and OCT enables direct 
visualization of the EZ line, whose characteristics such as integrity, intensity, and 
width have been correlated with different retinal disease processes. These 
imaging modalities are limited by their inability to scan beyond the central retina, 
the requirement of an intact EZ line (precluding patients with advanced-stage 
disease from analysis), and lack of direct assessment of function, which is 
ultimately what affects quality of life for patients. Nevertheless, structural and 
functional tests can complement each other to provide valuable data about the 
retina’s overall health and function. 
 
Looking forward, this study can be the basis of follow-up studies with increased 
sample sizes and power. The promising field of gene therapy for the treatment of 
inherited retinal degenerations may finally bring treatment options to patients who 
are eagerly anticipating clinical trials that will first need to characterize 
progression rates of disease. Future studies with sufficiently large enough 
cohorts can utilize mixed effect models to assess the effects of other variables 
such as disease stage, sex, and age on disease progression. They can also 
continue to look for the effects of mutation class and ring morphology on rates. 
Although rhodopsin mutations account for a large portion of autosomal dominant 
RP cases, the disease is relatively rare and the specific mutations even more so. 
A multicenter study would help increase the cohort size and improve the 
statistical confidence of any analyses, although care will have to be taken to 
ensure standardized imaging equipment and techniques. Studies with a longer 
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follow-up duration would also be helpful in capturing changes in rates over more 
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